Back to Research Hub
Syndax Pharmaceuticals, Inc.
SNDX
$20.81-0.40 (-1.89%)
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of…
StreetsValue research for Syndax Pharmaceuticals, Inc. (SNDX)
Members get the full report for Syndax Pharmaceuticals, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.